Human tumor antigens for cancer vaccine development

Rong Fu Wang, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

The adoptive transfer of tumor-infiltrating lymphocytes (TIL) along with interleukin (IL)-2 into autologous patients with cancer resulted in the objective regression of tumor, indicating that T cells play an important role in tumor regression. In the last few years, efforts have been made towards understanding the molecular basis of T-cell-mediated antitumor immunity and elucidating the molecular nature of tumor antigens recognized by T cells. Tumor antigens identified thus far could be classified into several catagories: tissue-specific differentiation antigens, tumor-specific shared antigens and tumor-specific unique antigens. CD4+ T cells play a central role in orchestrating the host immune response against cancer, infectious diseases and autoimmune diseases, and we thus have attempted to identify major histocompatibility complex (MHC) class II-restricted tumor antigens as well. The identification of tumor rejection antigens provides new opportunities for the development of therapeutic strategies against cancer. This review will summarize the current status of MHC class I- and class II-restricted human tumor antigens, and their potential application to cancer treatment.

Original languageEnglish (US)
Pages (from-to)85-100
Number of pages16
JournalImmunological Reviews
Volume170
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Cancer Vaccines
Neoplasm Antigens
Neoplasms
T-Lymphocytes
Major Histocompatibility Complex
Tumor-Infiltrating Lymphocytes
Adoptive Transfer
Differentiation Antigens
Cellular Immunity
Autoimmune Diseases
Interleukin-2
Communicable Diseases
Antigens
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

Human tumor antigens for cancer vaccine development. / Wang, Rong Fu; Rosenberg, Steven A.

In: Immunological Reviews, Vol. 170, 1999, p. 85-100.

Research output: Contribution to journalArticle

Wang, Rong Fu ; Rosenberg, Steven A. / Human tumor antigens for cancer vaccine development. In: Immunological Reviews. 1999 ; Vol. 170. pp. 85-100.
@article{2f0b044d2157415d86112cdf2ad275c5,
title = "Human tumor antigens for cancer vaccine development",
abstract = "The adoptive transfer of tumor-infiltrating lymphocytes (TIL) along with interleukin (IL)-2 into autologous patients with cancer resulted in the objective regression of tumor, indicating that T cells play an important role in tumor regression. In the last few years, efforts have been made towards understanding the molecular basis of T-cell-mediated antitumor immunity and elucidating the molecular nature of tumor antigens recognized by T cells. Tumor antigens identified thus far could be classified into several catagories: tissue-specific differentiation antigens, tumor-specific shared antigens and tumor-specific unique antigens. CD4+ T cells play a central role in orchestrating the host immune response against cancer, infectious diseases and autoimmune diseases, and we thus have attempted to identify major histocompatibility complex (MHC) class II-restricted tumor antigens as well. The identification of tumor rejection antigens provides new opportunities for the development of therapeutic strategies against cancer. This review will summarize the current status of MHC class I- and class II-restricted human tumor antigens, and their potential application to cancer treatment.",
author = "Wang, {Rong Fu} and Rosenberg, {Steven A.}",
year = "1999",
doi = "10.1111/j.1600-065X.1999.tb01331.x",
language = "English (US)",
volume = "170",
pages = "85--100",
journal = "Immunological Reviews",
issn = "0105-2896",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Human tumor antigens for cancer vaccine development

AU - Wang, Rong Fu

AU - Rosenberg, Steven A.

PY - 1999

Y1 - 1999

N2 - The adoptive transfer of tumor-infiltrating lymphocytes (TIL) along with interleukin (IL)-2 into autologous patients with cancer resulted in the objective regression of tumor, indicating that T cells play an important role in tumor regression. In the last few years, efforts have been made towards understanding the molecular basis of T-cell-mediated antitumor immunity and elucidating the molecular nature of tumor antigens recognized by T cells. Tumor antigens identified thus far could be classified into several catagories: tissue-specific differentiation antigens, tumor-specific shared antigens and tumor-specific unique antigens. CD4+ T cells play a central role in orchestrating the host immune response against cancer, infectious diseases and autoimmune diseases, and we thus have attempted to identify major histocompatibility complex (MHC) class II-restricted tumor antigens as well. The identification of tumor rejection antigens provides new opportunities for the development of therapeutic strategies against cancer. This review will summarize the current status of MHC class I- and class II-restricted human tumor antigens, and their potential application to cancer treatment.

AB - The adoptive transfer of tumor-infiltrating lymphocytes (TIL) along with interleukin (IL)-2 into autologous patients with cancer resulted in the objective regression of tumor, indicating that T cells play an important role in tumor regression. In the last few years, efforts have been made towards understanding the molecular basis of T-cell-mediated antitumor immunity and elucidating the molecular nature of tumor antigens recognized by T cells. Tumor antigens identified thus far could be classified into several catagories: tissue-specific differentiation antigens, tumor-specific shared antigens and tumor-specific unique antigens. CD4+ T cells play a central role in orchestrating the host immune response against cancer, infectious diseases and autoimmune diseases, and we thus have attempted to identify major histocompatibility complex (MHC) class II-restricted tumor antigens as well. The identification of tumor rejection antigens provides new opportunities for the development of therapeutic strategies against cancer. This review will summarize the current status of MHC class I- and class II-restricted human tumor antigens, and their potential application to cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=0032880649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032880649&partnerID=8YFLogxK

U2 - 10.1111/j.1600-065X.1999.tb01331.x

DO - 10.1111/j.1600-065X.1999.tb01331.x

M3 - Article

C2 - 10566144

AN - SCOPUS:0032880649

VL - 170

SP - 85

EP - 100

JO - Immunological Reviews

JF - Immunological Reviews

SN - 0105-2896

ER -